White House, CDC Warn Medetomidine Is Emerging In U.S. Fentanyl Supply

The White House drug policy office and CDC have issued a national alert warning first responders and doctors about medetomidine, a potent sedative now appearing in illicit fentanyl in U.S. communities.

Director of National Drug Control Policy Sara Carter said Monday, May 4, 2026, that this is the first time her office has partnered with the CDC on such an alert, and she warned the medetomidine-fentanyl combination "kills." The advisory says detections of medetomidine have risen since 2023, particularly in drug seizures in the Northeast and Midwest, and urges clinicians to be prepared for atypical sedative effects alongside opioid overdoses.

Carter said the alert is part of a broader Trump administration crackdown on cartels, citing expanded wastewater testing to spot new substances and a December 2025 move to classify fentanyl and its precursor chemicals as weapons of mass destruction, which broadened intelligence and military tools against trafficking networks.